CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Clinical trial NCT06128044 · TERMINATED

Trial details

NCT number: NCT06128044
Sponsor: Caribou Biosciences, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia Refractory

Start date: 2024-02-08
Primary completion: 2025-05-30
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.